Biovaxys Technology Corp (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has successfully completed the second tranche of its non-brokered private placement, raising $279,625 through the issuance of over 4.3 million units at $0.065 each, which includes a common share and a purchase warrant. The funds are earmarked for general working capital purposes and to advance the company’s business plans following its recent acquisition of a suite of immunotherapeutic assets. The securities issued are subject to a statutory hold period expiring four months and one day from the closing date.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
